Extremely Low Hepatitis C prevalence among HIV co-infected individuals in 4 countries in sub-Saharan Africa

LOAREC, Anne¹; CARNIMEO, Valentina¹; MOLFINO, Lucas²; KIZITO, Walter³; MUYINDIKE, Winnie⁴; ANDRIEUX-MEYER, Isabelle⁵; BALKAN, Suna⁶; NZOMUKUNDA, Yvonne³; MWANGA-AMUMPAIRE, Juliet¹,²; OUSLEY, Janet⁶; BYGRAVE, Helen⁸; MAMAN, David¹

1. Epicentre, Paris, France
2. Médecins Sans Frontières, Geneva, Switzerland
3. Médecins Sans Frontières, Brussels, Belgium
4. Mbarara Hospital, Ministry of Health ISS clinic, Uganda
5. Drugs for Neglected Diseases Initiative, Geneva, Switzerland
6. Médecins Sans Frontières, Paris, France
7. Mbarara University of Science and Technology, Mbarara, Uganda
8. Médecins Sans Frontières, Southern Africa Medical Unit, South-Africa

Correspondance: Dr. Anne Loarec, MSF-Epicentre, 55 Rue Crozatier, 75012 Paris, France
Anne.LOAREC@epicentre.msf.org

Running Head: Low sub-Saharan African HCV prevalence
Key words: HCV screening, Serology, Viral Confirmation, Malawi, Kenya, Mozambique, Uganda
Funding: This study was funded through a grant from UNITAID

Text: 995/1000

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

*Submitted as a Research Letter*
SUMMARY

A multicentric, retrospective case-series analysis (facility-based) in 5 sites across Kenya, Malawi, Mozambique, and Uganda screened HIV-positive adults for Hepatitis C Virus (HCV) antibodies using Oraquick© rapid testing and viral confirmation (in 3 sites). Results found substantially lower prevalence than previously reported for these countries compared to previous reports, suggesting that targeted integration of HCV screening in African HIV programs may be more impactful than routine screening.

Prior research on Hepatitis C virus (HCV) infection in sub-Saharan Africa is limited and methodologically inconsistent, often characterized by poor categorization of individuals from high risk groups, lack of virological confirmation of active disease, and bias from environmental factors (e.g. reduced case detection specificity from Schistosoma) [1-4]. Furthermore, reported HCV co-infection prevalence is highly variable in Africa, ranging from 3.3% in southern regions to 42.3% in the north.

We conducted a retrospective case-series analysis in health facilities and hospitals in five African countries with varied HIV prevalence settings, the largest observational analysis of HIV/HCV co-infection in Africa to date.

Patients were selected from five Médecins Sans Frontières facilities in four countries with varying HIV prevalence: Mbarara, Uganda (7.9% adult HIV prevalence); Maputo, Mozambique (16.9%); Chiradzulu, Malawi (17.0%), Kibera, Kenya (an impoverished quarter of Nairobi) (12.6%), and rural Homa Bay County, Kenya (27.1%) [5-9]. Patients were eligible if they were ≥18 years-old, infected with HIV, and screened for HCV between January 2014 and December 2016. HIV patients with long term anti-retroviral therapy exposure and with uncomplicated, advanced
stages of HIV disease were included. People-who-use-drugs (PWUD) were included at one site (Mozambique).

HCV screening procedures were similar across sites. HCV care was integrated into routine care for HIV differently depending on the site: during patients’ initial diagnosis or during follow-up counseling sessions (Uganda) or upon initiation of ART care or during annual HIV viral load testing (Kenya-Kibera). At two sites, HCV screening was already integrated into pre-existing procedures for observational studies exploring the pathology of long term ART recipients (Malawi) and hospitalized inpatients (Kenya-Homa Bay)\(^\text{[10]}\). For each site, procedures were adapted for the local context and according to national policies, conducted in collaboration with the national Ministry of Health.

Preliminary serological screening of whole blood samples was conducted at all sites using the OraQuick© HCV rapid qualitative test (OraSure Technologies, USA), a WHO pre-qualified immunoglobulin G HCV antibody immunoassay (sensitivity=100% [95% CI: 97.8-100.0], specificity=99.4% [95% CI: 97.3-99.8])\(^\text{[11]}\). Antibody-positive patients were further confirmed for replicative infection using two different Real-Time Polymerase Chain Reaction (RT-PCR) viral load measures: PCR Roche COBAS®Ampliprep/COBAS®TaqMan (Mozambique and Uganda) and Abbott m2000® (Kenya-Kibera). Patients with confirmed active infection received baseline clinical assessments and viral genotyping from accredited laboratories using either dried blood spot cards (Uganda) or frozen plasma (Kenya and Mozambique). Upon confirmation of a positive result, all patients were offered standard treatment with Direct Acting Antivirals (DAA).

Study databases used RedCap v.5.7.3 software (Vanderbilt, USA) in Malawi, Kenya-Homa Bay, and Mozambique; EpiData v.3.1 (Denmark, Europe) in Uganda; and Microsoft Excel in Kenya-Kibera. Analysis occurred in STATA v.13 (College Station, USA). Upper and lower confidence
bounds were calculated using an open source sample size calculator (University of California San Francisco, USA)\textsuperscript{[12]}. All studies were ERB approved, sought consent, and applied data protection practices for participants.

In total, 15,336 HIV patients were screened for HCV antibodies, and 0.4% tested positive (Table 1). HCV antibody prevalence among those screened was higher in Mozambique (30/2600; 1.15%, 95% CI: 0.81-1.64) compared to Malawi (2/385; 0.5%, 95% CI: 0.14-1.87), Uganda (18/7500, 0.24%, 95% CI: 0.15-0.38), and Kenya (Kibera: 10/4500; 0.22%, 95% CI: 0.12-0.41; Homa Bay: 1/351; 0.28%, 95% CI: 0.05-1.59). In Mozambique, a lot of patients were PWUD; among the screened PWUD, 79% presented HCV positive Antibody.

Active HCV infection confirmed by HCV viral replication (Kenya-Kibera, Mozambique, Uganda), was low: 0.04% (n=2/4500; 0.01-0.17), 1% (n=26/2600; 95% CI: 0.68-1.46), and 0.07% (n=5/7500; 0.03-0.16). Characteristics of individuals with confirmed replicative viral HCV infection (e.g. genotype, viral load, treatment, and demographics) are shown in Table 1.

HCV-antibody and PCR-positivity prevalence measured in our study were substantially lower than pooled estimates from other studies conducted in the same five countries \textsuperscript{[1]}, neighboring African countries, and other low-resource contexts \textsuperscript{[13-15]}. This may be explained by a number of differences unique to our study: patient characteristics (e.g. exclusively HIV-infected patients, PWUD); differences in screening strategies; or variation in the performance of serological rapid diagnostic tests (e.g. Oraquick\textsuperscript{©} was the only WHO pre-qualified RDT at the time of study, it has not been widely tested in field situations in African settings or in HIV infected populations \textsuperscript{[16, 17]}).

There was some variation between our sample sites. The Mozambican PWUD sub-group observed the highest levels of antibody-prevalence and viral confirmation, confirming that even
when prevalence is low, PWUD are especially susceptible to HCV infection and may require targeted screening. In Uganda, viral genotyping revealed exclusively Type 4 HCV, diverging from previous evidence finding only Type 1 in the country \cite{1,18}. Linked with choice of regimen, the difference is important while research on this issue is evolving and little data is available overall. In addition, gender differences between sites (high proportion of females in Ugandan HCV-confirmed patients, high proportion of males in Mozambican HCV-confirmed patients), were likely due to gendered risk behaviors, such as injection drug use. There were some limitations in this study. Except the Mozambican PWUD, these patients may not have had HCV risk factors. Database limitations prevented analysis of a potential cohort effect when individuals had already died. Information on co-infection with HCV and Schistosomiasis was unavailable, though prior literature has suggested causes high HCV false positivity screening percentage in these moderate to high Schistosoma prevalent countries. Statistical variance (“false-positive paradox”) may have led to more false positive results compared to true positives when low incidence rates were lower than false positive rates \cite{3,19,20}.

In summary, our results demonstrate the feasibility of large-scale HCV screening during HIV care using simplified rapid testing, but also confirm that HCV does not seem to be the public health burden in the sites investigated that it is in other regions, particularly among people living with HIV. Future HCV screening strategies in the region should consider these findings when determining policy (MSF has already replaced systematic HCV screening for HIV-positive patients at study sites with a risk factor and symptomatic screening algorithm, prioritizing PWUD). Policy changes will be more efficient if they also increase access to testing and treatment.
ACKNOWLEDGEMENTS

We would like to acknowledge the communities and patients involved in this analysis, as well as collaborating Ministries of Health and other partners in the 5 sites. This study was made possible by a grant from UNITAID (N° SPHQ14-LOA-217) and MSF funding.

CONFLICT OF INTEREST
The authors declare no competing interests in the publication of this study.
REFERENCES


2. Lauer GM, Kim AY. **Spontaneous resolution of chronic hepatitis C virus infection: are we missing something?** *Clin Infect Dis* 2006; 42(7):953-954.


9. Statistics UBo. **Demographic and Health Survey.** In. Rockville, Maryland, USA; 2016.


Table 1: HCV screening results among HIV patients and characteristics of virologically confirmed CHC patients in 5 sub-Saharan sites, 2014-2016

<table>
<thead>
<tr>
<th>Sites</th>
<th>Population</th>
<th>Screened Patients</th>
<th>Reactive HCV RDT Positive Serology N (% [95%CI])</th>
<th>Detectable HCV VL/Tested</th>
<th>Confirmed CHC/total screened %</th>
<th>Confirmed CHC Patients</th>
<th>Median Age (year)</th>
<th>% Female</th>
<th>Genotype n/N (%)</th>
<th>Median Viral Load (IU/mL)</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mozambique</td>
<td>Advanced HIV or PWUD</td>
<td>2600</td>
<td>30 (1.15% [0.81-1.64])</td>
<td>26/30 (86%)</td>
<td>1.0% (0.68-1.46)</td>
<td>40</td>
<td>0/26 (0%)</td>
<td>GT1 13/16 (81%)</td>
<td>769,000</td>
<td>Sof+Dac</td>
<td></td>
</tr>
<tr>
<td>Kenya-Kibera</td>
<td>HIV+</td>
<td>4500</td>
<td>10 (0.22% [0.12-0.41])</td>
<td>2/10 (20%)</td>
<td>0.04% (0.01-0.17)</td>
<td>36</td>
<td>1/2 (50%)</td>
<td>GT4 2/2 (100%)</td>
<td>3,014,583</td>
<td>Sof+Led</td>
<td></td>
</tr>
<tr>
<td>Uganda</td>
<td>HIV+</td>
<td>7500</td>
<td>18 (0.25% [0.15-0.38])</td>
<td>5/17 (29%)</td>
<td>0.07% (0.03-0.16)</td>
<td>43</td>
<td>5/5 (100%)</td>
<td>GT4 5/5 (100%)</td>
<td>2,990,000</td>
<td>Sof+Led</td>
<td></td>
</tr>
<tr>
<td>Malawi</td>
<td>HIV+ on ART ≥10 years</td>
<td>365</td>
<td>2 (0.52% [0.14%-1.87%])</td>
<td>N/A</td>
<td>N/A</td>
<td>XX</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kenya-Homa Bay</td>
<td>HIV+ inpatients</td>
<td>351</td>
<td>1 (0.28% [0.05-1.59])</td>
<td>N/A</td>
<td>N/A</td>
<td>XX</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOTAL LS</td>
<td>--</td>
<td>15,316</td>
<td>61 (0.3%)**</td>
<td>33/57 (57.9%)</td>
<td>--</td>
<td>6/33</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*In Uganda, 1 patient was lost to follow up between their serological test and viral confirmation

**Aggregated analysis only, not a pooled/weighted figure

PWUD=People Who Use Drugs; RDT=Rapid Diagnostic Test; CHC=Chronic Hepatitis C; Sof=sofosbuvir; Dac=Daclatasvir; Led=Ledipasvir; GT=Genotype